2-[3-[2-(4,5-diphenyl-2-oxazolyl) ethyl] phenoxy] acetic acid (BMY 42393): A new, structurally-novel prostacyclin partial agonist: 1) inhibition of platelet aggregation and mechanism of action
- 15 April 1994
- journal article
- Published by Elsevier in Thrombosis Research
- Vol. 74 (2) , 115-123
- https://doi.org/10.1016/0049-3848(94)90004-3
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Prostacyclin agonists reduce early atherosclerosis in hyperlipidemic hamsters. Octimibate and BMY 42393 suppress monocyte chemotaxis, macrophage cholesteryl ester accumulation, scavenger receptor activity, and tumor necrosis factor production.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993
- Nonprostanoid prostacyclin mimetics. 3. Structural variations of the diphenyl heterocycle moietyJournal of Medicinal Chemistry, 1992
- Nonprostanoid prostacyclin mimetics. 2. 4,5-diphenyloxazole derivatives.Journal of Medicinal Chemistry, 1992
- Structure-activity relationships associated with 3,4,5-triphenyl-1H-pyrazole-1-nonanoic acid, a nonprostanoid prostacyclin mimeticJournal of Medicinal Chemistry, 1992
- Primate vascular responses to octimibate, a non‐prostanoid agonist at the prostacyclin receptorBritish Journal of Pharmacology, 1991
- PGI2-receptors and molecular mechanisms in platelets and vasculature: State of the artPharmacological Research Communications, 1987
- The single prostacyclin receptor of gel-filtered platelets provides a correlation with antiaggregatory potency of PGI2 mimicsThrombosis Research, 1987
- Platelet actions of stable carbocyclic analogues of prostacyclin.Circulation, 1985
- A potent new inhibitor of platelet aggregation and experimental thrombosis, anagrelide (BL-4162A)Thrombosis Research, 1979
- A highly sensitive adenylate cyclase assayAnalytical Biochemistry, 1974